The efficacy of a leukotriene receptor antagonist in the treatment of human rectal aberrant crypt foci: a nonrandomized, open-label, controlled trial

[1]  S. Satapathy,et al.  Montelukast, a CysLT1 receptor antagonist, reduces colon cancer stemness and tumor burden in a mouse xenograft model of human colon cancer. , 2018, Cancer letters.

[2]  J. O’Sullivan,et al.  Evaluation of Cysteinyl Leukotriene Signaling as a Therapeutic Target for Colorectal Cancer , 2016, Front. Cell Dev. Biol..

[3]  J. Hung,et al.  Corrigendum: Cysteinyl Leukotriene Receptor Antagonists Decrease Cancer Risk in Asthma Patients , 2016, Scientific Reports.

[4]  M. Huang,et al.  Cysteinyl Leukotriene Receptor Antagonists Decrease Cancer Risk in Asthma Patients , 2016, Scientific Reports.

[5]  M. Rubinstein,et al.  Leukotriene C4 is the major trigger of stress-induced oxidative DNA damage , 2015, Nature Communications.

[6]  Hyeong Su Kim,et al.  The cysteinyl leukotriene receptor CysLTR1 mediates Th17 cell migration (CAM4P.156) , 2015, The Journal of Immunology.

[7]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[8]  A. Sjölander,et al.  CysLT1R Antagonists Inhibit Tumor Growth in a Xenograft Model of Colon Cancer , 2013, PloS one.

[9]  M. Peters-Golden,et al.  Antileukotriene agents for the treatment of lung disease. , 2013, American journal of respiratory and critical care medicine.

[10]  Hirokazu Takahashi,et al.  Natural history of human aberrant crypt foci and correlation with risk factors for colorectal cancer. , 2012, Oncology reports.

[11]  A. Zauber,et al.  Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. , 2012, The New England journal of medicine.

[12]  Hirokazu Takahashi,et al.  Investigation of the Prevalence and Number of Aberrant Crypt Foci Associated with Human Colorectal Neoplasm , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[13]  J. Drazen,et al.  Asthma treatment guidelines meet the real world. , 2011, The New England journal of medicine.

[14]  Zhiyuan Shen.  Genomic instability and cancer: an introduction. , 2011, Journal of molecular cell biology.

[15]  Hirokazu Takahashi,et al.  Metformin Suppresses Colorectal Aberrant Crypt Foci in a Short-term Clinical Trial , 2010, Cancer Prevention Research.

[16]  R. DuBois,et al.  Eicosanoids and cancer , 2010, Nature Reviews Cancer.

[17]  P. Maisonneuve,et al.  Five-year risk of colorectal neoplasia after negative colonoscopy. , 2008, The New England journal of medicine.

[18]  H. Brenner,et al.  Five-year risk of colorectal neoplasia after negative colonoscopy. , 2008, The New England journal of medicine.

[19]  Edward S. Kim,et al.  Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial , 2008, Cancer Prevention Research.

[20]  N. Arber,et al.  Chemoprevention of Colorectal Cancer , 2007, Digestion.

[21]  S. Paruchuri,et al.  Endogenous production of leukotriene D4 mediates autocrine survival and proliferation via CysLT1 receptor signalling in intestinal epithelial cells , 2006, Oncogene.

[22]  Jeffrey M Drazen,et al.  COX-2 inhibitors--a lesson in unexpected problems. , 2005, The New England journal of medicine.

[23]  O. Brawley,et al.  Colorectal carcinoma in black and white race , 2003, Cancer and Metastasis Reviews.

[24]  R. Capocaccia,et al.  Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence , 2001, Gut.

[25]  E. Kliewer,et al.  Cancer risk in patients with inflammatory bowel disease , 2001, Cancer.

[26]  Junji Kato,et al.  Aberrant crypt foci of the colon as precursors of adenoma and cancer , 1998, The New England journal of medicine.

[27]  Y. Yazaki,et al.  Effects of sulindac on sporadic colorectal adenomatous polyps. , 1997, Gut.

[28]  T. Shimoyama,et al.  Effect of leukotriene C4D4 antagonist on colonic damage induced by intracolonic administration of trinitrobenzene sulfonic acid in rats , 1995, Journal of Gastroenterology.

[29]  A. Zauber,et al.  Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. , 1993 .

[30]  L. Roncucci,et al.  Classification of aberrant crypt foci and microadenomas in human colon. , 1991, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[31]  T. P. Pretlow,et al.  Aberrant crypts: putative preneoplastic foci in human colonic mucosa. , 1991, Cancer research.

[32]  L. Roncucci,et al.  Identification and quantification of aberrant crypt foci and microadenomas in the human colon. , 1991, Human pathology.

[33]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.

[34]  A. Sjölander,et al.  CysLT 1 R Antagonists Inhibit Tumor Growth in a Xenograft Model of Colon Cancer , 2013 .

[35]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[36]  Hirokazu Takahashi,et al.  Life style-related diseases of the digestive system: colorectal cancer as a life style-related disease: from carcinogenesis to medical treatment. , 2007, Journal of pharmacological sciences.

[37]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[38]  S. Paruchuri,et al.  The leukotriene receptor CysLT1 and 5-lipoxygenase are upregulated in colon cancer. , 2003, Advances in experimental medicine and biology.

[39]  J. Faivre,et al.  Chemoprevention of colorectal cancer. , 1999, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[40]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[41]  T. P. Pretlow,et al.  Aberrant crypts in human colonic mucosa: Putative preneoplastic lesions , 1992, Journal of cellular biochemistry. Supplement.